Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a challenging disease process with a 5-year survival rate of only 11%. Neoadjuvant therapy in patients with localized pancreatic cancer has multiple theoretical benefits, including improved patient selection for surgery, early delivery of systemic therapy,...

Full description

Bibliographic Details
Main Authors: Anish J. Jain, Jessica E. Maxwell, Matthew H. G. Katz, Rebecca A. Snyder
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
pancreatic cancer
pancreatic adenocarcinoma
neoadjuvant therapy
resectability
vascular resection
prehabilitation
Online Access:https://www.mdpi.com/2072-6694/15/16/4174

Internet

https://www.mdpi.com/2072-6694/15/16/4174

Similar Items